Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer

2019-09-09T20:15:07Z (GMT) by Zaina T. Al-Salama
Compliance with Ethical Standards

Funding The preparation of this review was not supported by any external funding.

Conflicts of interestZaina T. Al-Salama is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest


Additional information about this Adis Drug Review can be found here


Abstract



Apalutamide (marketed as Erleada®) is an oral non-steroidal next-generation selective inhibitor of the androgen receptor (AR), and is approved in several countries, including in the EU and USA for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). In men with nmCRPC who were receiving androgen-deprivation therapy (ADT) and had a high risk of metastases in SPARTAN, apalutamide significantly prolonged metastasis-free survival (MFS) compared with placebo, with consistent benefits demonstrated across subgroups. The addition of apalutamide to ongoing ADT significantly prolonged time to metastasis and progression-free survival (PFS) compared with placebo, and was associated with maintenance of health-related quality of life (HR-QOL). Apalutamide was generally well tolerated in SPARTAN, with fatigue being the most frequently reported adverse event. Given the available evidence, apalutamide with ongoing ADT represents an emerging treatment option for use in patients with nmCRPC who are at a high risk of developing metastatic disease.



© Springer Nature Switzerland AG 2019